Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 1, 2025
Distillery Therapeutics
Inhibiting CNDP2 to disrupt nutrient cooperativity in cancer
BioCentury | Mar 26, 2025
Discovery & Translation
Science Spotlight: New insight into LAG3’s checkpoint function
BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
BioCentury | Feb 13, 2025
Emerging Company Profile
Unnatural: Expanding the macrocyclic peptide chemical space
Company applying small molecule optimization techniques to peptides with a robotic synthesis platform
BioCentury | Nov 13, 2024
Discovery & Translation
Science Spotlight: How extrachromosomal DNA drives cancer
BioCentury’s roundup of translational innovation features two trios of papers: one on genetic control of cancer and the other on MASLD markers
BioCentury | Jul 20, 2024
Product Development
Oncology at AstraZeneca: The journey to the top
A Q&A with EVP of oncology R&D, Susan Galbraith: Part 1
BioCentury | Jul 18, 2024
Emerging Company Profile
Clasp: Optimizing T cell engagers for tighter binding, more cancer killing
Launched in March with $150M, Clasp is designing T cell-engaging bispecifics to better fit the immune synapse
BioCentury | Jun 6, 2024
Product Development
Solid tumor immunotherapies headline ASCO’s first-in-human studies
A focus on first-in-class innovation and solid tumor applications
BioCentury | Apr 11, 2024
Data Byte
Fewer SPACs announcing mergers
Disclosures of new merger targets have remained low for three straight quarters
Items per page:
1 - 10 of 863